Oncotarget

Clinical Research Papers:

Treatment of primary intracranial germ cell tumors: Single center experience with 42 clinically diagnosed cases

Qun-Ying Yang, Cheng-Cheng Guo, Mei-Ling Deng, Jian Wang, Jing Wang, Fu-hua Lin, Ji Zhang, Xiao-Bing Jiang, Yong-Gao Mou and Zhong-Ping Chen _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:60665-60675. https://doi.org/10.18632/oncotarget.10218

Metrics: PDF 1454 views  |   HTML 1815 views  |   ?  


Abstract

Qun-Ying Yang1,*, Cheng-Cheng Guo1,*, Mei-Ling Deng2, Jian Wang1, Jing Wang1, Fu-hua Lin1, Ji Zhang1, Xiao-Bing Jiang1, Yong-Gao Mou1, Zhong-Ping Chen1

1State Key Laboratory of Oncology in South China, Department of Neurosurgery/Neuro-Oncology at The Cancer Center of Sun Yat-sen University, Collaborative Innovation Center of Oncology, Guangzhou 510060, China

2State Key Laboratory of Oncology in South China, Department of Radiotherapy at The Cancer Center of Sun Yat-sen University, Collaborative Innovation Center of Oncology, Guangzhou 510060, China

*These authors have contributed equally to this work

Correspondence to:

Zhong-Ping Chen, email: chenzhp@sysucc.org.cn

Keywords: primary intracranial germ cell tumor, clinical diagnosis, diagnostic radiotherapy, diagnostic chemotherapy

Received: January 27, 2016     Accepted: June 10, 2016     Published: June 22, 2016

ABSTRACT

Background and Objective: Primary intracranial germ cell tumors (GCTs) are a class of heterogeneous tumors. Surgery can quickly relieve tumor compression and provide histological diagnosis. It is very difficult to treat some patients who are unable to be pathologically diagnosed. We aimed to analyze clinically diagnosed GCTs patients.

Methods: Patients clinically diagnosed as primary intracranial GCTs were included in this study.

Results: From 2002 to 2015, 42 patients clinically diagnosed with primary intracranial GCTs received chemotherapy and/or radiotherapy. Patients were assigned to diagnostic chemotherapy group (25 cases), diagnostic radiotherapy group (5 cases) and gamma knife radiosurgery group (12 cases) based on their initial anti-tumor therapy. The 5-year survival rates were 85.8%, 75.0% and 63.6%, respectively. There were no statistically significant difference (p value = 0.44). Patients were assigned to the group (30 cases) with secretory tumors and the group (12 cases) with non-secretory tumors based on their levels of tumor makers. The 5- year survival rates were 80.7% and 68.6%, respectively. There were no statistically significant difference (p value = 0.49).The major adverse reactions were grade III - IV bone marrow suppression with an incidence of 35.2% and grade II- III nausea/vomiting with an incidence of 45.8%.

Conclusion: Surgical removal of tumor or biopsy is recognized as the most accurate method to determine the pathological property of tumor. But for some patients who can not be pathologically diagnosed, they can receive comprehensive treatments such as chemotherapy combined with radiotherapy, and some of them can still have good responses.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10218